Pharmacokinetic bioequivalence, safety and acceptability of Ornibel®, a new polymer composition contraceptive vaginal ring (etonogestrel/ethinylestradiol 11.00/3.474 mg) compared with Nuvaring® (etonogestrel/ethinylestradiol 11.7/2.7 mg).
Jaime AlgortaMaria DiazRaquel de BenitoMarc LefebvreEric SicardMilton FurtadoPedro Antonio RegidorCelestino RonchiPublished in: The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception (2018)
Ornibel® is bioequivalent to Nuvaring® in terms of efficacy, safety, tolerability and acceptability. The new polymer composition provides Ornibel® with more stability and gradual hormonal release during the first day of use, particularly for ethinylestradiol.